Latest news
JAZZ Maintains Overweight Rating by JP Morgan -- Price Target Ra - GuruFocusGuruFocus · Tue, 04 Aug 2026 20:59:03 GMTJAZZ Maintained by Piper Sandler -- Price Target Raised to $310 - GuruFocusGuruFocus · Tue, 04 Aug 2026 15:53:41 GMTJAZZ Maintains Overweight Rating -- Price Target Raised to $270 - GuruFocusGuruFocus · Tue, 04 Aug 2026 12:09:01 GMTMorgan Stanley Adjusts PT on Jazz Pharmaceuticals to $280 From $245, Maintains Overweight Rating - marketscreener.commarketscreener.com · Tue, 04 Aug 2026 09:21:38 GMTThese Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results - SahmSahm · Tue, 04 Aug 2026 07:00:00 GMT